Semaglutide, Tirzepatide, and Retatrutide: Key Differences
Tirzepatide achieves the greatest weight loss (15–20% body weight reduction), semaglutide provides proven cardiovascular and renal protection, and retatrutide—a triple receptor agonist still in development—shows the most potent metabolic effects in preclinical studies. 1
Mechanism of Action
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1, stimulating insulin secretion and suppressing glucagon release in a glucose-dependent manner while delaying gastric emptying. 2
Tirzepatide is a dual GIP/GLP-1 receptor agonist that targets both glucose-dependent insulinotropic polypeptide and GLP-1 receptors, providing enhanced metabolic effects beyond single-receptor stimulation. 3
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously—the broadest mechanism of the three agents. 3, 4 The role of glucagon receptor stimulation in treating diabetes and obesity remains poorly defined and requires clarification. 5
Weight Loss Efficacy
Tirzepatide produces 15–20% mean body weight reduction at 72 weeks in adults with type 2 diabetes, compared to 5–10% with semaglutide—this represents the strongest evidence-based difference between the two approved agents. 1
Retatrutide demonstrates even greater weight loss potential: in phase 2 trials, weight reduction ranged from 7.2% to approximately 18% as doses increased from 1 mg to 12 mg over 24 weeks. 6 Network meta-analysis shows retatrutide 12 mg achieves 22.10% body weight reduction and retatrutide 8 mg achieves 20.70% reduction—both superior to tirzepatide 15 mg (16.53%) and semaglutide. 4
Tirzepatide is superior to semaglutide in head-to-head comparisons: tirzepatide produces an additional 6.10% percentage weight reduction (95% CI: 3.64–8.57), 4.55 kg absolute weight loss (95% CI: 1.28–7.83), 1.71 kg/m² BMI reduction (95% CI: 0.08–3.34), and 2.89 cm waist circumference reduction (95% CI: 1.25–4.53) compared to semaglutide. 7
Glycemic Control
Tirzepatide demonstrates superior glycemic efficacy over semaglutide: HbA1c reduction is 0.33% greater (95% CI: 0.20–0.46) and fasting blood glucose is reduced by an additional 10.39 mg/dL (95% CI: 4.48–16.29). 7
Retatrutide lowers blood glucose but does not outperform tirzepatide or semaglutide in glycemic control—tirzepatide exhibits the best glucose-lowering effects among the three agents. 8
Semaglutide reduces fasting glucose by 29 mg/dL (22%), 2-hour postprandial glucose by 74 mg/dL (36%), and mean 24-hour glucose by 30 mg/dL (22%) compared to placebo. 2
Cardiovascular and Renal Outcomes
Semaglutide has high-certainty evidence for reducing major adverse cardiovascular events (MACE) in patients with established cardiovascular disease (SUSTAIN-6 trial) and major kidney disease events in patients with type 2 diabetes and chronic kidney disease (FLOW trial). 1
Real-world data from 10,625 matched patients show semaglutide reduces revised 3-point MACE by 29% (HR 0.71; p=0.046) and revised 5-point MACE by 22% (HR 0.78; p=0.040) compared to tirzepatide in patients with overweight/obesity and established atherosclerotic cardiovascular disease. 9 In per-protocol analysis with treatment adherence, semaglutide's advantage increases to 57% reduction in rMACE-3 (HR 0.43; p=0.005) and 43% reduction in rMACE-5 (HR 0.57; p=0.003). 9
Tirzepatide's cardiovascular effects remain uncertain—the SURPASS-CVOT trial is ongoing and no outcome data are yet available; current evidence for cardiovascular and renal benefit is low to very low certainty. 1
Retatrutide has no cardiovascular outcome trial data—it remains investigational for obesity and type 2 diabetes. 5, 6
Safety Profile
All three agents produce similar gastrointestinal adverse events: nausea occurs in approximately 25% of patients, vomiting and diarrhea affect up to 10%. 1
Tirzepatide may cause slightly higher rates of severe gastrointestinal events leading to discontinuation compared to semaglutide (moderate certainty evidence). 1
Retatrutide's most frequent adverse events are gastrointestinal (nausea, diarrhea, vomiting), consistent with the class effect. 6 Retatrutide increases heart rate by up to 6.7 beats/min, which may be detrimental and offset some benefits of weight loss. 6
All three agents increase the risk of gallbladder or biliary disease, particularly during rapid weight loss. 1 Both tirzepatide and semaglutide carry warnings for pancreatitis, though causality is not established; therapy must be discontinued immediately if severe abdominal pain develops. 1
Contraindication for all three: patients with personal or family history of medullary thyroid carcinoma or relevant genetic mutations should avoid all GLP-1 receptor agonists. 1
Clinical Decision Algorithm
For patients WITHOUT established cardiovascular disease or chronic kidney disease (lower-risk):
- Tirzepatide is the first-line agent to achieve maximal weight loss and glycemic improvement (strong recommendation from BMJ guideline). 1
- Retatrutide may offer even greater weight loss once approved, but lacks outcome data. 4, 6
For patients WITH established cardiovascular disease, heart failure, or chronic kidney disease (moderate-to-high risk):
- Semaglutide (or another GLP-1-RA with proven outcome data) must be retained—tirzepatide should not replace it as sole cardioprotective/renoprotective therapy (strong recommendation). 1
- Real-world evidence confirms semaglutide's superiority for cardiovascular risk reduction in this population. 9
If switching from semaglutide to tirzepatide for greater weight loss:
- An SGLT2 inhibitor must be initiated or continued to preserve cardiovascular and renal protection (strong recommendation). 1
Combination therapy:
- Tirzepatide can be combined with SGLT2 inhibitors but must never be co-administered with another GLP-1-RA (strong recommendation). 1
Renal Function Considerations
Semaglutide requires no dose adjustment in renal impairment, including end-stage renal disease—no clinically relevant change in pharmacokinetics occurs. 2
Tirzepatide shows favorable renal outcomes in retrospective cohorts: 42% reduction in all-cause mortality (HR 0.58; 95% CI 0.45–0.75), 48% lower risk of composite renal events (HR 0.52; 95% CI 0.37–0.73), and 22% reduction in acute kidney injury (HR 0.78; 95% CI 0.70–0.88) compared to GLP-1 receptor agonists. 10
Retatrutide demonstrates superior effectiveness in improving renal function in db/db mice, markedly suppressing pro-inflammatory cytokines (TNF-α, caspase-1, NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, collagen I) more effectively than liraglutide or tirzepatide. 8
Guideline Society Positions
The American Diabetes Association endorses dual GIP/GLP-1 agonists (tirzepatide) as preferred first-choice therapy for patients with type 2 diabetes and obesity, based on superior weight-loss outcomes (strong recommendation). 11, 1
The BMJ Living Guideline (2025) emphasizes the trade-off between proven cardiovascular/renal benefit of GLP-1-RAs (semaglutide) and greater weight-loss advantage of tirzepatide, recommending individualized decision-making based on cardiovascular risk stratification (moderate certainty). 1
The ADA/KDIGO 2022 guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred add-on therapy for CKD patients who do not achieve glycemic targets with metformin and/or SGLT2 inhibitors. 10